Treatment of neonatal seizures with carbamazepine

Area of Science:

• Neonatal Neurology
• Pharmacology
• Clinical Pediatrics

Background:

• Carbamazepine is a well-established anticonvulsant in adults and older children.
• Its use as a primary anticonvulsant in neonates has been limited.
• Neonatal seizures, particularly those due to hypoxic-ischemic encephalopathy, require effective treatment options.

Purpose of the Study:

• To evaluate the long-term safety and efficacy of carbamazepine in neonates.
• To assess carbamazepine absorption, therapeutic levels, and elimination half-life in this population.
• To determine the anticonvulsant effect and side effect profile of carbamazepine in neonates.

Main Methods:

• Ten full-term neonates with hypoxic-ischemic encephalopathy-related seizures received carbamazepine via nasogastric tube.
• Loading doses were followed by two different maintenance regimens (21 mg/kg/day or 15 mg/kg/day).
• Therapy duration ranged from 3 to 9 months, with intensive drug level monitoring.

Main Results:

• Excellent carbamazepine absorption was observed in neonates, with therapeutic levels reached within 2-4 hours.
• Seizure control was excellent, with only two patients experiencing a single seizure post-treatment initiation.
• No significant gastrointestinal, hepatic, hematologic, renal, or dermatologic side effects were reported.

Conclusions:

• Carbamazepine demonstrates potential as an effective anticonvulsant for neonatal seizures.
• The drug is well-absorbed and tolerated in neonates, even those who are critically ill.
• This preliminary study supports further investigation into carbamazepine for neonatal seizure management.